Accolade (ACCD), a company specializing in personalized healthcare, has announced a definitive agreement for acquisition by Transcarent, an innovative platform focused on health and care solutions. The transaction is valued at approximately $621 million in cash.
This offer represents a significant 110% premium over Accolade's stock closing price as of January 7th.
Through this acquisition, Transcarent aims to provide high-quality, affordable healthcare services and enhance the personalized experiences for its members.
The funding for this transaction will be secured through a fully committed equity financing, primarily backed by General Catalyst and Glen Tullman's 62 Ventures.
The deal is anticipated to conclude by the second quarter of 2025.
Following the completion of the acquisition, Accolade will transition into a privately held entity and its common stock will no longer be listed on the Nasdaq.
Currently, ACCD shares are trading at $6.87, reflecting a 105.08% increase, or $3.52, on the Nasdaq.
The material has been provided by InstaForex Company - www.instaforex.com
This offer represents a significant 110% premium over Accolade's stock closing price as of January 7th.
Through this acquisition, Transcarent aims to provide high-quality, affordable healthcare services and enhance the personalized experiences for its members.
The funding for this transaction will be secured through a fully committed equity financing, primarily backed by General Catalyst and Glen Tullman's 62 Ventures.
The deal is anticipated to conclude by the second quarter of 2025.
Following the completion of the acquisition, Accolade will transition into a privately held entity and its common stock will no longer be listed on the Nasdaq.
Currently, ACCD shares are trading at $6.87, reflecting a 105.08% increase, or $3.52, on the Nasdaq.
The material has been provided by InstaForex Company - www.instaforex.com